Comparative proteomics identified statistically robust overexpression of several inflammatory cytokines, specifically IL6, IL18, CCL7, CXCL10, and CXCL11, which could be targeted to prevent untoward immune-inflammatory effects in COVID-19 patients. Here, CXCL11 is linked to COVID-19.